Theralase’s Ruvidar Boosts Cancer Drug Efficacy

Theralase Technologies (TSE:TLT) has released an update.

Theralase Technologies Inc. has announced a breakthrough in cancer treatment with its lead compound, Ruvidar, which when combined with the established cancer drug BCG, forms a new compound, RuBCG. RuBCG has shown to significantly improve the effectiveness of BCG in killing cancer cells by reversing the BCG bacterium’s cell wall charge, potentially offering a more efficacious treatment option for Non-Muscle Invasive Bladder Cancer.

For further insights into TSE:TLT stock, check out TipRanks’ Stock Analysis page.